IO

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

Retrieved on: 
Tuesday, November 28, 2023
Cardiology, Software, Biometrics, Health, Health Technology, Technology, Apps, Applications, Mobile, Wireless, Food and Drug Administration, Food, Therapy, PDT Partners, Investment, Traction, Better, Interest-only loan, Patient, Type 2 diabetes, FDA, Financial management, IO, Pharmaceutical industry

Better Therapeutics successfully negotiated an amendment to its debt facility with Hercules Capital,Inc., granting the company the opportunity to extend the Interest Only (IO) period until mid-2024, redeem up to $2.5 million of debt without prepayment penalties, and potentially eliminate the minimum cash covenant.

Key Points: 
  • Better Therapeutics successfully negotiated an amendment to its debt facility with Hercules Capital,Inc., granting the company the opportunity to extend the Interest Only (IO) period until mid-2024, redeem up to $2.5 million of debt without prepayment penalties, and potentially eliminate the minimum cash covenant.
  • The amendment also grants the Company an option to convert a portion of the debt into equity, under certain conditions.
  • These measures, along with other operational plans, are expected to improve the company’s financial position by approximately $5 million through the first quarter of 2024.
  • Frank Karbe, President and Chief Executive Officer at Better Therapeutics, expressed confidence in the company's trajectory, stating, "We recognize the importance of prudent financial management and are confident that these measures will position Better Therapeutics for sustained success.

Belden SPS 2023 Exhibit Showcases Industrial Automation Solutions

Retrieved on: 
Tuesday, November 14, 2023
Technology, Security, Telecommunications, Professional Services, Networks, Internet, Hardware, Electronic Design Automation, Data Analytics, Data Management, Acquisition, NYSE, 10 AM, Organization, Plant, ROI, SPS, KPI-driven code analysis, BDC, Artificial intelligence, Automation, Machine learning, Computer security, Digitalization, Hirschman, IO, Digitization, AI, AWS, Time-Sensitive Networking, Mobile phone, Cryptocurrency, Nightclub, Management, Online shopping

Belden (NYSE: BDC), a leading global supplier of network infrastructure and digitization solutions, will showcase its Industrial Automation Solutions portfolio at the 32nd edition of SPS, the trade fair for smart and digital automation, held in Nuremberg on 14 to 16 November 2023.

Key Points: 
  • Belden (NYSE: BDC), a leading global supplier of network infrastructure and digitization solutions, will showcase its Industrial Automation Solutions portfolio at the 32nd edition of SPS, the trade fair for smart and digital automation, held in Nuremberg on 14 to 16 November 2023.
  • Belden helps industrial organizations counter escalating threats with cybersecurity solutions that protect infrastructure from the IO block to the cloud.
  • Belden Horizon Data Operations (BHDO) and Belden Horizon Data Manager (BHDM): Industrial organizations need vendor-neutral solutions to harvest and contextualize critical operational data to support advanced analytics.
  • In addition to spotlighting Belden solutions, SPS 2023 features several thought leadership presentations by Belden experts.

AdGrid.IO and Infinity Partnerships Launch Voices™ Marketplace

Retrieved on: 
Thursday, November 16, 2023
Marketplace, Entrepreneurship, BIPOC, Interactive media, EBONY, Multimedia, IO, Music

NEW YORK, Nov. 16, 2023 /PRNewswire/ -- The Voices™ Marketplace has recently launched to solve the problem of scale in multicultural digital advertising.

Key Points: 
  • NEW YORK, Nov. 16, 2023 /PRNewswire/ -- The Voices™ Marketplace has recently launched to solve the problem of scale in multicultural digital advertising.
  • The Voices™ Marketplace is a joint venture between Infinity Partnerships , the most inclusive ad tech consultancy and AdGrid.
  • To date, Infinity Partnerships and ADGrid.io have partnered with EBONY to power the EBONY Alliance and Mundo Now to power the Mundo Now Projec t , both of which empower diverse content creators.
  • Advertisers want to help diverse publishers but are also looking for performative campaigns - with the Voices™ marketplace we are delivering this."

JelloX Unveils New Research at ESMO Congress 2023

Retrieved on: 
Tuesday, November 14, 2023
Medicine, Research, Spacecraft, Pathology, Conference, Breast cancer, ESMO, Silicon, Patient, Pharmacy, Risk assessment, Oncology, Cancer, IO, 3D, Biomarker, AI, Neoplasm, Immunotherapy, Medical imaging, Medical device

SANTA CLARA, Calif. and HSINCHU, Nov. 14, 2023 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, is announcing new research and conference milestones, coinciding with its 5th anniversary in November 2023. With significant parts of the medical field starting to leverage AI for pharmaceutical R&D and patient risk assessment, JelloX continues to distinguish itself as an early adopter of AI applied to cancer pathology.

Key Points: 
  • To explore JelloX's AI-powered 3D pathology solutions, please contact: [email protected]
    An influential conference in the European oncology space, ESMO Congress 2023 took place from October 20 to 24 and featured significant dialogue around the latest advancements in immunotherapy (IO), antibody-drug conjugates (ADCs), and AI.
  • Invited to present, JelloX's unique application of AI in 3D pathology for cancer drew significant interest from attendees, and its latest research demonstrated new possibilities for biomarker-based patient screening prior to IO treatments.
  • "We estimate that 40% of cancer patients can benefit from AI-analyzed 3D pathology, especially those undergoing immunotherapy," noted Dr. Lin.
  • Our solutions are critical to matching the right patients to the right drugs and to identifying suitable candidates for pharmaceutical research."

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 8, 2023
Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Hospitals, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, NSCLC, GBM, DHL, Mantle cell lymphoma, Artificial intelligence, BBB, Lung, Rituximab, IO, USD, AI, Starlight, Lung cancer, Liver, Permeability, Antibody, Cancer, Machine learning, Pancreatic cancer, Brain, NHL, Safety, Therapy, Liquid biopsy, Patient, D, Central nervous system, DNA, Automation, ATM, Johns Hopkins School of Medicine, PD-1, Spacecraft, Fox Chase Cancer Center, MCL, Society, Education, Incidence, Patent, Bone marrow, Harmonic, CNS, Drug development, PDX, Algorithm, Breast, Glioblastoma, Metadata, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Cryptocurrency, Lantern

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter ended September 30, 2023.
  • Lantern plans to release additional details and data on this set of results with LP-284 in this setting in the coming month.
  • G&A Expenses: General and administrative expenses were approximately $1.3 million for the quarter ended September 30, 2023, compared to approximately $1.4 million for the quarter ended September 30, 2022.
  • Earnings Call and Webinar Details:
    Lantern will host its third quarter 2023 earnings call and webinar today, November 8, 2023, at 4:30 p.m.

Ventana Introduces Veyron V2 -- World's Highest Performance Data Center-Class RISC-V Processor and Platform

Retrieved on: 
Tuesday, November 7, 2023
RISE, Chiplet, Economics, UCIe, Speech, Composable disaggregated infrastructure, SDK, Ecosystem, IO, Overalls, AI, Software development kit, IP, Veyron, Memory, Mobile phone, Cryptocurrency, Video game

CUPERTINO, Calif., Nov. 7, 2023 /PRNewswire/ -- Ventana Micro Systems Inc. today announced the second generation of its Veyron family of RISC-V processors. The new Veyron V2 is the highest performance RISC-V processor available today and is offered in the form of chiplets and IP.

Key Points: 
  • The new Veyron V2 is the highest performance RISC-V processor available today and is offered in the form of chiplets and IP.
  • Ventana Founder and CEO Balaji Baktha will share the details of Veyron V2 today during his keynote speech at the RISC-V Summit North America 2023 in Santa Clara, California.
  • This gain has been made possible through significant microarchitecture enhancements, superior high performance processor fabric architecture, enhanced cache hierarchy, and the addition of a high performance vector processor.
  • Ventana provides a Software Development Kit (SDK) which includes a comprehensive set of software building blocks already proven on Ventana's RISC-V platform.

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Research, NSCLC, Therapy, Acquisition, ADC, Clinical trial, Spacecraft, Cancer, IO, Lead, CFO, Lung cancer, Investment, Patient, Vaccine, Bank, Pharmaceutical industry, Palladium, Security (finance), Cryptocurrency

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugates (ADCs) and immune-oncology (IO) therapeutics to target difficult-to-treat cancers, today announced initiatives to extend its cash runway, reported financial results for the quarter ended September 30, 2023, and provided a corporate update. The company ended the third quarter of 2023 with approximately $134.4 million in cash, cash equivalents, restricted cash and short-term investments.

Key Points: 
  • The company ended the third quarter of 2023 with approximately $134.4 million in cash, cash equivalents, restricted cash and short-term investments.
  • We believe the progress we are making through the dose escalation portion of our trial speaks to the potential safety profile of our ADC drug candidate.
  • On August 23, 2023, Pyxis Oncology announced the successful completion of its acquisition of Apexigen, Inc., in an all-stock transaction valued at approximately $10.7 million.
  • As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092.

Basis Technologies and LG Ad Solutions Announce Exclusive Partnership for Connected TV Political Advertising

Retrieved on: 
Tuesday, November 7, 2023
Attention, Comparison of multi-paradigm programming languages, CTV, LG, Advertising, Growth, Politics, SSP, Basis Technology, Partnership, IO, Consultant, ACR, PMP, Automation, Video game, Marketing, Basis, Magnite

CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Basis Technologies , a global provider of programmatic advertising and media automation solutions along with LG Ad Solutions , a global leader in connected TV (CTV) and cross-screen advertising, today announced an exclusive partnership for activation of U.S. political advertising, effective immediately through the end of 2024.

Key Points: 
  • CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Basis Technologies , a global provider of programmatic advertising and media automation solutions along with LG Ad Solutions , a global leader in connected TV (CTV) and cross-screen advertising, today announced an exclusive partnership for activation of U.S. political advertising, effective immediately through the end of 2024.
  • “TV advertising has long been a pivotal element of political marketing,” said Serge Matta, President, Global Ad Sales at LG Ad Solutions.
  • “However, as traditional linear TV viewership declines, as Basis' ad spend data indicates , CTV advertising became the dominant story across the 2022 elections with continued growth expected in 2024.
  • “LG Ad Solutions’ direct-to-glass CTV advertising will be a game-changer for 2024 campaigns,” said Tyler Kelly, President, Basis Technologies.

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor

Retrieved on: 
Tuesday, November 7, 2023
Society for Immunotherapy of Cancer, Merkel-cell carcinoma, Radiation, PD-L1, MD–PhD, NSCLC, AACR, Trial of the century, PD, RT, Nivolumab, DCR, Pembrolizumab, Monroe Dunaway Anderson, PD-1, RCC, HIV disease progression rates, PI, SITC, Immunotherapy, SD, Hodgkin lymphoma, Solar cycle 1, Drug discovery, Cancer, Webcast, RECIST, Solar cycle 2, University, Society, Monocyte, MD Anderson Cancer Center, Patient, Toxicity, PR, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Palladium, SCCHN, IO, Plinabulin

Based on preclinical models, where plinabulin plus radiation and anti-PD-1 antibody enhances dendritic cell (DC) activation, T-cell proliferation, and abscopal effect, a clinical study was initiated to test these findings.

Key Points: 
  • Based on preclinical models, where plinabulin plus radiation and anti-PD-1 antibody enhances dendritic cell (DC) activation, T-cell proliferation, and abscopal effect, a clinical study was initiated to test these findings.
  • 11 out of 14 patients eligible for efficacy assessment per RECIST criteria and had measurable target lesion responses in the non-irradiated tumor lesion.
  • Please reference conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson.
  • A live webcast will be available on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section.

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 7, 2023
Research, Research and development, NSCLC, ESMO, Multiple myeloma, Therapy, TIGIT, Pembrolizumab, Investment, Head, CD96, Place of birth, R, IO, GSK, Patient, Administration, Neck, Palladium, Pharmaceutical industry, HNSCC

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • and GOSSELIES, Belgium, Nov. 07, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • Research and Development (R&D) Expenses: R&D expenses were $30.6 million for the quarter ended September 30, 2023, as compared to $23.9 million for the same quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $12.6 million for the quarter ended September 30, 2023, as compared to $10.8 million for the same quarter of 2022.
  • The increases were primarily due to increases in headcount and related costs compared to the same quarter and nine months last year.